UPS has announced its new president of global helathcare and life sciences (HCLS) unit: Wes Wheeler.
Wheeler's appointment follows UPS's announcement in October, which revealed that the company would align all of its HCLS operations and commercial groups into a single unit.
The new unit includes Marken, Polar Speed and UPS's 114 healthcare-dedicated facilities. The unit provide supply chain management, cold chain, clinical trials, global transportation and other healthcare service operations.
Wheeler was formerly chief executive of UPS-owned subsidiary Marken, which was acquired by UPS in 2016. Prior to his new role, Wheeler was vice president of marketing, and senior vice president of global manufacturing supply at Glaxo (now GlaxoSmithKline), and chief executive and president at four companies, including Patheon, Valeant, DSM Pharmaceuticals and Marken.
During Wheeler's 40-year career, he was involved in key functional areas in pharmaceuticals, including manufacturing, drug development, supply chain logistics, marketing and engineering.
David Abney, UPS chairman and chief executive, commented: “Wheeler has an impressive career and deep experience in the clinical trials, pharmaceutical, biotech and medical device industries. His expertise will complement our strategic healthcare growth and technology initiatives.”
“We look forward to Wheeler continuing our commitment to putting healthcare customers’ needs first, while ensuring UPS meets supply chain demands with quality assurance, innovation and control,” Abney added.
